|Jason S. Lewis, PhD; Professor, Emily Tow Jackson Chair in Oncology, Memorial Sloan Kettering Cancer Center|
Wednesday, February 6, 2019 3pm—4pm
BMI Conference Room HSC-L3 Room 045
• Introduce reasons for very high attrition in the development of new drugs.
• Understand the difference between thermodynamics and kinetics of drug-target interactions.
• Recognize that drug selectivity has two components: thermodynamic and kinetic.
• Demonstrate that dosing frequency can be reduced using drugs that dissociate slowly from their targets thereby improving safety.
• Introduce PK/PD models that link target engagement with drug concentration (PK) and drug efficacy (PD).
Learn about target vulnerability.
Jason S. Lewis Ph.D. is the Vice Chair for Research, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facili-ty. He heads a laboratory in the Sloan Kettering Institute’s molecular pharmacology program and is a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. He has published more than 200 papers, books, book chapters, and reviews on cancer imaging.
Questions? Please call the Biomedical Informatics Department at 631-638-2590. CME credit is NOT being oﬀered for this event